Speaking at the FT Pharmaceutical & Biotechnology conference earlier this week, Ipsen’s CCO said that pharma manufacturers need to focus more on the ‘why’.
PPD puts the spotlight on special patient populations by supporting clinical trials with Asian participants, preparing developers to expand into the Asian market.
FDA’s Janet Woodcock testifies to Congress about the potential risks to US national security of the pharmaceutical industry’s reliance on Chinese imports.
The company’s Shanghai facility passes the European regulator’s inspection with no ‘critical’ or ‘major’ findings regarding the commercial products produced at the site.
Representatives from the EMA and China’s NMPA convene to share expertise on GMP for APIs, GCP standards, and on the environmental impact of manufacturing.
As part of an evaluation of its manufacturing network, the company concluded that the Ringaskiddy production building was no longer a competitive, long-term option.
Takeda has sold selected prescription and OTC products to Acino covering its Near East, Middle East and Africa portfolio, as it looks to trim down its portfolio following the acquisition of Shire.
Broad adoption of blockchain technology requires manufacturers to look at their investments in the supply chain, just as they look at R&D, AmerisourceBergen executive says.
With nitrosamines back in the headlines due to the recent discovery of contaminants in ranitidine, the EMA releases the five potential causes of the impurities plaguing the industry.
AstraZeneca enters a $270m deal with Cheplapharm to divest seven drugs, in order to reduce its portfolio of ‘mature’ medicines and reinvest in other therapeutic areas.
